Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ITRM Stock Summary
- Iterum Therapeutics plc's stock had its IPO on May 25, 2018, making it an older stock than only 4.47% of US equities in our set.
- ITRM's price/sales ratio is 1,370.36; that's higher than the P/S ratio of 99.56% of US stocks.
- Revenue growth over the past 12 months for Iterum Therapeutics plc comes in at -95.74%, a number that bests just 0.64% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ITRM, based on their financial statements, market capitalization, and price volatility, are SCYX, CBMG, TOCA, INO, and ITCI.
- ITRM's SEC filings can be seen here. And to visit Iterum Therapeutics plc's official web site, go to www.iterumtx.com.
ITRM Stock Price Chart Interactive Chart >
ITRM Price/Volume Stats
|Current price||$2.03||52-week high||$2.99|
|Prev. close||$2.01||52-week low||$0.45|
|Day high||$2.05||Avg. volume||19,016,742|
|50-day MA||$1.32||Dividend yield||N/A|
|200-day MA||$1.17||Market Cap||363.65M|
Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.
ITRM Latest News Stream
|Loading, please wait...|
ITRM Latest Social Stream
View Full ITRM Social Stream
Latest ITRM News From Around the Web
Below are the latest news stories about Iterum Therapeutics plc that investors may wish to consider to help them evaluate ITRM as an investment opportunity.
Shareholders May Not Be So Generous With Iterum Therapeutics plc's (NASDAQ:ITRM) CEO Compensation And Here's Why
In the past three years, the share price of Iterum Therapeutics plc ( NASDAQ:ITRM ) has struggled to grow and now...
The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.
We've got one more day of trading left in the week and we're starting it off with the biggest-pre-market stock movers for Friday!
Iterum Therapeutics plc (NASDAQ: ITRM ) has concluded a late-cycle meeting with the FDA related to its application for sulopenem etzadroxil/probenecid. Sulopenem is under review as a treatment for uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen. The agency … Full story available on Benzinga.com
The big gain came after the company announced that the U.S. Food and Drug Administration (FDA) wouldn't require an advisory committee review of the regulatory filing for sulopenem etzadroxil/probenecid in treating urinary tract infections. Iterum submitted its filing in January of this year. The FDA originally planned to convene an advisory committee to review the application on June 2, 2021.
ITRM Price Returns
Continue Researching ITRMWant to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:
Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch